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receptor agonist therapy in diabetic kidney
disease: the VALIDATE-D study
Jenifer M Brown, Kristina Secinaro, Jonathan S Williams and Anand Vaidya*Abstract
Background: Insufficient vitamin D status and increased renin-angiotensin system (RAS) activity have been
associated with renal-vascular disease and nephropathy in diabetes. Accumulating evidence indicates that vitamin
D receptor (VDR) activation lowers unfavorable RAS activity; however, more human intervention studies evaluating
whether this mechanism could influence diabetic kidney disease are needed. We previously reported that both
vitamin D levels and genetic variation at the VDR predict human RAS activity, and that vitamin D therapy can lower
RAS activity in non-diabetics. The VALIDATE-D study is a randomized, placebo-controlled, intervention study
designed to extend these findings by evaluating whether direct VDR activation in diabetes lowers circulating and
local renal-vascular tissue RAS activity (Aims 1 and 2) in a manner similar to the action of ACE inhibitors (Aim 3).
Methods/Design: Forty subjects with type 2 diabetes, microalbuminuria, and without chronic kidney disease will
be recruited to undergo detailed assessment of the RAS before and after randomization to calcitriol 0.75 mcg/day
or placebo. Primary analyses will evaluate whether calcitriol therapy reduces circulating and renal-vascular tissue-
RAS activity in comparison to placebo. All subjects will thereafter be treated with lisinopril and followed for
3.5 months to evaluate whether combination therapy (calcitriol + lisinopril vs. placebo + lisinopril) additively or
synergistically improves renal-vascular function, and lowers proteinuria.
Discussion: The VALIDATE-D study is the first human intervention study to evaluate whether direct VDR activation
can lower the human RAS in diabetes, compared to the effect of an ACE inhibitor, and whether this mechanism
can translate to clinically relevant endpoints for diabetic kidney disease. The outcomes of VALIDATE-D will have
major implications for the recommendation of vitamin D supplementation for the primary prevention of kidney
complications in diabetes.
Trial registration: ClinicalTrials.gov, NCT01635062
Keywords: Vitamin D, Calcitriol, Renin, Angiotensin, Diabetes, KidneyBackground
The link between vitamin D and kidney disease, particularly
in the setting of human diabetes, has received much atten-
tion [1,2]. Observational and limited interventional studies
have supported a renoprotective benefit to higher vitamin
D levels and vitamin D supplementation [3-7]; however,
there is a need for more dedicated human intervention
studies to confirm these findings. One of the main* Correspondence: avaidya1@partners.org
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reproduction in any medium, provided the orproposed mechanisms linking vitamin D with renal-
vascular and kidney disease is regulation of the renin-
angiotensin system (RAS) [8,9]. Since both of these
hormonal systems have complex genetic and environ-
mental regulatory steps (Figure 1), carefully controlled
interventional studies that evaluate both mechanisms
of action and clinical outcomes are needed to distin-
guish the hormonal interplay that is likely involved for
vitamin D therapy to influence kidney disease.
Both excess activity of the renin-angiotensin system
(RAS) and insufficient vitamin D status have been impli-
cated in the development of renal-vascular disease thatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 The proposed interaction between vitamin D and RAS metabolism. Renin catalyzes the conversion of angiotensinogen to
angiotensin I, which is further converted to the vasoactive peptide angiotensin II. Angiotensin II is a direct vasoconstricter, and can also ilicit
aldosterone secretion from the adrenal cortex. Under physiologic situations, activation of the RAS in response to renal-vascular hypo-perfusion
serves to increase blood pressure and renal salt retention. However, in pathologic states (such as in diabetes and obesity), inappropriately high
RAS activity contributes to vascular and kidney diseases. Vitamin D3 is largely produced in the skin with exposure to ultraviolet radiation, but may
also be ingested orally. This precursor is hydroxylated to 25-hydroxyvitamin D (25[OH]D) and 25(OH)D serves as the stable barometer of clinical
“vitamin D status.” Under the control of parathyroid hormone and calcium status, 25(OH)D can be hydroxylated to form the active vitamin D
receptor (VDR) agonist 1,25-dihydroxyvitamin D (1,25[OH]2D). Activation of the VDR by 1,25(OH)2D is known to influence the regulation and
expression of a myriad of genes, including renin.
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mediate renal-vascular disease via its circulating compo-
nents, and additionally the locally expressed renal-
vascular tissue-RAS also contributes to the development
of kidney disease [11,12]. Excess renal-vascular tissue-
RAS activity has been implicated in the development of
diabetic nephropathy; RAS inhibitors [13-15], as well as
favorable vitamin D status [5,16,17], may mitigate this
effect.
Animal studies have shown that the activation of the
vitamin D receptor (VDR) by 1,25-dihydroxyvitamin D
(1,25[OH]2D) negatively regulates renin expression and
thereby lowers RAS activity [9,18] (Figure 1). In mouse
models of diabetes, both VDR-agonists and RAS-
inhibitors blunted the development of diabetic nephropa-
thy when given alone, but the combination (VDR-agonist +
RAS-inhibitor) synergistically prevented the development of
diabetic nephropathy via down-regulation of the renal-
vascular tissue-RAS [19-21]. We, and others, have reported
findings that translate these animal experiments to humans:
the combination of vitamin D levels and genetic variation at
the human VDR predicts RAS activity [22-24]. Large obser-
vational studies have shown that the prevalence of chronic
kidney disease and proteinuria (a marker of kidney disease
progression) are associated with lower 25(OH)D levels[3,25,26]. Due to their cross-sectional design, these afore-
mentioned studies could not reveal causality or confirm the
mechanism linking vitamin D-VDR interactions and renal
outcomes. A few human interventions have demonstrated
that VDR agonists may reduce proteinuria [2,7], but these
studies were confined to populations with established
chronic kidney disease (CKD), and evaluation of the RAS
was not undertaken. We recently completed a pilot human
intervention study in non-diabetics without CKD that dem-
onstrated that high-dose vitamin D3 therapy improved
renal-vascular hemodynamics by lowering renal-vascular
tissue-RAS activity [5]. This latter effect was similar to that
induced by an angiotensin converting enzyme (ACE) inhibi-
tor, thereby further supporting a renoprotective effect of
vitamin D therapy [5].
In light of these novel human results translated from
animal experiments, we hypothesize that activation of
the VDR represents a method to lower renal-vascular
tissue-RAS activity in human diabetes, and could
therefore play an important role in the primary pre-
vention of diabetic nephropathy. We therefore designed
the VALIDATE-D study: an ongoing randomized, double-
blinded, placebo-controlled study to assess whether direct
VDR activation: Aim 1) lowers circulating RAS activity in
human diabetes; Aim 2) lowers renal-vascular tissue-RAS
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with ACE inhibition, exerts an additive or synergistic ef-
fect on the renal-vascular tissue-RAS and proteinuria.
Methods/Design
Study population and recruitment
The VALIDATE-D study will enroll 40 adults, aged
18–70 years, withType 2 diabetes (T2DM), microalbuminuria,
and without known CKD (estimated glomerular filtration
rate > 60 mL/min). Subjects will be recruited from the
local community and from the outpatient clinics of the
Division of Endocrinology, Diabetes, and Hypertension
within the Department of Medicine at Brigham and
Women’s Hospital, Boston, USA. Eligibility will be assessed
at an in-person screening visit involving detailed history,
physical examination, and laboratory assessment.
Inclusion criteria include T2DM that is controlled with
diet, oral hypoglycemic agents, incretin analogues, or a
single basal insulin injection; microalbuminuria; normal
blood pressure or stage 1 hypertension treated with 0–1
antihypertensive agents; and normal blood cell counts,
liver function, and electrocardiogram.
Exclusion criteria include CKD (glomerular filtration
rate < 60 mL/min); poorly controlled T2DM (defined as
HbA1c > 8.5% or the use of >1 daily insulin injection or
a history or retinopathy); stage 2–3 hypertension or the
use of more than one antihypertensive agent; kidney
stones, parathyroid or granulomatous disorders, liver or
heart failure, or coronary artery disease or congestive heart
failure or cerebrovascular accidents. All subjects provide
informed consent, and all study procedures have been ap-
proved by the Brigham & Women’s Hospital institutional
and ethics board as well as the Brigham and Women’sCalcitriol
HSLS
Circulating
RAS Renal-Vascular RAS 
& Urine Protein
LS
Placebo
LS
Medication
Washout Circula
RA
AIMS 1 & 2
TIME 0-2 MOS 1 WK 1 WK 3 WKS
VISIT 1 2 3 4 5
Figure 2 VALIDATE-D study schema: subjects will be screened and the
anti-hypertensive medications (when applicable). Aim 1: The circulating
calcitriol/placebo (visits 2 & 5). Aim 2: The renal-vascular tissue-RAS will
& 6). Aim 3: All subjects will then receive lisinopril 5 mg/d in addition
(calcitriol + lisinopril vs. placebo + lisinopril) on the renal-vascular tissu
and phosphate will be monitored weekly throughout the study for safHospital Center for Clinical Investigation. Recruitment was
initiated in September 2012 and is expected to be com-
pleted by September 2016.
Study protocol overview
A detailed study schema is shown in Figure 2. All study
visits will occur in the Clinical Research Center (CRC) at
Brigham and Women’s Hospital. Studies will be performed
in the CRC in order to control posture, time of day, dietary
intake, and medication administration, since all of these
factors are known to influence RAS activity. In brief, de-
tailed profiling of the RAS will be performed at baseline
before any intervention (Visits 2 & 3), again after
double-blinded randomization to calcitriol or placebo
(Visits 5 & 6) to assess whether calcitriol lowers RAS
activity, and again after the addition of lisinopril to the
blinded study drug to assess for an additive or synergistic
relationship between VDR-agonist and ACE inhibitor
therapy on the RAS and proteinuria (Visits 8 & 13).
Washout
It is well known that many medications interfere with
physiologic RAS responses or with the assays that meas-
ure the RAS. To optimize the reliability and accuracy of
RAS measurements, medications that interfere with RAS
assessments will be withdrawn. Subjects using RAS inhibi-
tors (such as angiotensin converting enzyme [ACE] inhibi-
tors, angiotensin receptor blockers, or mineralocorticoid
receptor antagonists) will stop their medications for
2 months prior to study. Subjects using beta-blockers or
diuretics will stop their medications for 1 month prior to
study, whereas those on calcium channel blockers will
stop for 2 weeks prior to study. Medication washout willCalcitriol + Lisinopril
HS
HS
HS
Placebo + Lisinopril
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n may undergo a medication washout to withdraw interfering
RAS will be assessed on LS diet before and after randomization to
be assessed on HS diet before and after calcitriol/placebo (visits 3
to calcitriol/placebo to assess the impact of combination therapy
e-RAS (visits 6 & 8) and proteinuria (visits 6, 8, 13). Serum calcium
ety, at each visit and at designated safety checks (visits 4, 7, 9–12).
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scribed safety protocols [5] after providing and instructing
each subject on how to use a home sphygmomanometer.
As previously described, in cases where hypertension
(159/99 mmHg) results following withdrawal of an antihy-
pertensive medication, amlodipine will be used to lower
blood pressure as it has a neutral effects on RAS activity.Study diets
All study procedures will be conducted using one of two
specifically designed study diets.Low-salt diet
The low salt (LS) diet includes 10 mEq of sodium,
100 mEq of potassium, and <600 mg of calcium per day.
The purpose of this diet is to induce maximal stimula-
tion of RAS components to allow for adequate measure-
ments of the circulating RAS. Subjects will consume the
LS diet for 1 week prior to study visits where the circu-
lating RAS will be measured (Visits 2 and 5). All daily
meals and food intake during the LS dietary phase will
be prepared and provided to study participants by the
CRC dietary kitchen staff.Renal-Vascular
Tissue-RAS activity
Renal-Vascular
Response to AngIIHigh-salt diet
The high sat (HS) diet includes 200 mEq of sodium,
50 mEq of potassium, and <600 mg of calcium per day.
The purpose of this diet is to induce maximal suppres-
sion of the circulating RAS components in order to most
effectively measure the renal-vascular tissue-RAS, as
previously described [5,17]. Subjects will consume the
HS diet for 1 week prior to study visits where the renal-
vascular tissue-RAS will be evaluated (Visits 3, 6, and 8).
The HS diet involves consumption of an ad lib diet, with
supplements provided to achieve the sodium and potas-
sium contents.HIGH
LOW
HIGH
LOW
Figure 3 Reciprocal relationship between renal-vascular tissue-
RAS activity and the renal-vascular response to angiotensin II.
A blunted response to angiotensin II reflects a high level of local,
endogenous, renal-vascular tissue-RAS activity (the smaller the
decline in renal plasma flow in response to an infusion of
angiotensin II, the greater the activity of the local renal-vascular
tissue-RAS). Conversely, a robust response to angiotensin II is
observed when tissue-RAS activity is low.Low calcium diet
Subjects will be instructed and taught to restrict dietary
calcium intake during the LS and HS dietary phases
(<600 mg/day), and also during the duration of the study
in between study visits (<1000 mg/day). The purpose of
calcium restriction is to minimize the risk of hypercalce-
mia and hyperphosphatemia associated with calcitriol
administration; this risk is negligible in the context of
low dietary calcium intake [27-29]. A registered dietician
will coach subjects throughout the study on restricting
calcium intake and will provide materials to guide diet-
ary intake at home (Dietary Calcium Intake Recommen-
dations Additional file 1). Compliance with study diets
will be confirmed by 24-hour urine collections obtained
at every study visit.Baseline assessments of the circulating and renal-vascular
tissue-RAS (Visits 2 & 3)
After a screening visit (Visit 1) and a potential antihy-
pertensive washout phase, all subjects will undergo base-
line assessments to characterize the circulating and
renal-vascular tissue-RAS.Circulating RAS on LS diet (Visit 2)
Study visit 2 is designed to measure the baseline circulat-
ing RAS under conditions designed to induce maximal
stimulation of the circulating RAS: restricted dietary so-
dium intake and upright posture. After one week of LS
diet consumption, subjects are studied at 8 AM in the
morning (Figure 2). Subjects will maintain an upright
standing posture for at least 1 hour. Blood samples are
obtained at the end of the postural phase to measure
circulating RAS components (plasma renin activity,
angiotensn II, aldosterone).Renal-vascular tissue-RAS on HS diet (Visit 3)
Study visit 3 is designed to assess baseline renal-vascular
tissue-RAS activity by measuring changes in renal
plasma flow (RPF) in response to an infusion of exogen-
ous angiotensin II. Angiotensin II is a vasopressor that
specifically interacts with angiotensin receptors to in-
duce renal-vascular vasoconstriction resulting in a de-
crease in RPF. The magnitude of the decline in RPF to
angiotensin II is inversely related to renal-vascular
tissue-RAS activity (Figure 3); greater renal-vascular re-
sponses to angiotensin II signify lower local tissue-RAS
activity [5,30,31]. Using this physiologic methodology,
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an indirect method to assess the human renal-vascular
tissue-RAS.
To adequately measure the renal-vascular tissue-RAS,
subjects are studied on a HS diet and in overnight su-
pine posture to suppress endogenous circulating RAS
components, thereby amplifying measurable RPF re-
sponses to angiotensin II [32]. After completing one
week of HS diet, subjects will be admitted to the CRC
and maintained supine overnight and throughout the
study procedures on the following morning. In the
morning, two intravenous lines will be placed to facili-
tate infusion of study drugs and frequent blood sam-
pling. Weight-based para-aminohippurate (PAH) will
then be infused and its clearance used to measure RPF
throughout the duration of the study visit [5]. After
allowing PAH concentrations to reach a steady state over
60 minutes, blood will be sampled to establish the base-
line RPF. Angiotensin II will then be infused at 0.3 ng/
kg/min for 45 minutes and escalated to 1 ng/kg/min for
an additional 45 minutes to assess dose–response char-
acteristics. PAH will be measured during and after each
angiotensin II infusion to measure RPF dynamics. Blood
pressure will be monitored closely throughout the infu-
sions based on standardized safety protocols [5] that we
have extensive experience performing in our CRC. The
study visit will end upon completion of the angiotensin
II infusions, and subjects will be discharged to undergo
randomization to the study drug.
Randomization to study drug
Following study visit 3, subjects will be randomized to ei-
ther calcitriol 0.75 mcg/day or placebo arm using a 2 block
randomization. Double-blinded randomization will be
performed by the investigational drug pharmacy at our in-
stitution, and neither the subjects nor the investigators will
know the identity of the randomized study drug.
The influence of calcitriol on the RAS (Visits 5 & 6)
Circulating RAS on LS diet (Visit 5)
After 2 weeks of daily calcitriol or placebo, subjects will re-
turn on LS diet and complete visit 5, which is identical to
visit 2. Aim 1 of this study (to assess whether direct VDR
activation lowers circulating RAS activity in human dia-
betes) is executed in study visits 2 and 5. Anticipated Re-
sults: It is anticipated that calcitriol therapy will lower
circulating RAS components (plasma renin activity and
angiotensin II) when compared to placebo, demonstrating
for the first time that VDR agonism can inhibit the circu-
lating RAS in human diabetes.
Renal-vascular tissue-RAS on HS diet (Visit 6)
After a third week on the study drug, subjects will return
on HS diet for an overnight CRC study visit 6, that isidentical to Visit 3. This visit will permit assessment of
study Aim 2 (to assess whether direct VDR activation
lowers renal-vascular tissue-RAS activity in human
diabetes) by comparing the renal-vascular tissue-RAS
activity before and after calcitriol/placebo. Anticipated
Results: It is anticipated that calcitriol therapy will
raise basal RPF and increase the RPF sensitivity to
angiotensin II, thereby demonstrating that VDR activa-
tion improves renal-vascular hemodynamics by lower-
ing local renal-vascular RAS activity in human diabetics
without CKD.The influence of combination VDR-agonist and ACE
inhibitor therapy on the renal-vascular tissue RAS (Visit 8)
Upon completing study visit 6, all subjects will receive
lisinopril (initially 2.5 mg daily, which will be increased
to 5 mg daily after one week, unless blood pressures are
below 90/50 mmHg or subjects experience orthostatic
symptoms) in addition to their randomized study drug
(Figure 2). After 2 weeks of daily combined therapy
(calictirol + lisinopril or placebo + lisinopril), subjects will
return on the HS diet for a final inpatient CRC visit that
is identical to study visits 3 & 6. Comparing the out-
comes of study visits 6 and 8 will permit evaluation of
Aim 3 of this study (to assess whether direct VDR acti-
vation in combination with ACE inhibition exerts an
additive or synergistic effect on the renal-vascular tissue-
RAS and proteinuria). Anticipated Results: Combination
therapy (calcitriol + lisinopril) will additively or synergis-
tically raise RPF and increase the RPF sensitivity to
angioensin II infusion, reflecting decreased renal-vascular
tissue-RAS activity when compared to placebo + lisinopril.The influence of chronic combination therapy on
proteinuria (Visit 13)
Following completion of study visit 8, subjects will be
discharged home to continue both the study drug and
lisinopril for three months of long-term therapy (Figure 2).
For the final visit of the study, subjects will return after one
week of HS diet with a completed 24-hour urine collection,
which will be analyzed for protein. The 24-hour urine pro-
tein measured at this visit will be compared using repeated
measures analyses to the urine protein levels obtained from
24-hour urine collections completed at each inpatient visit
on HS dietary balance (visits 3, 6, 8). Anticipated Results:
Combination therapy (calcitriol + lisinopril) will additively or
synergistically lower proteinuria when compared to
placebo + lisinopril, thereby paralleling prior animal
studies that showed that the combination of VDR
agonist + conventional RAS inhibitor therapy induced
synergistic renoprotective benefits in mouse models of
diabetes [19-21].
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Calcium/Phosphate
To minimize the risk of hypercalcemia due to calcitriol,
all subjects will undergo laboratory evaluation of serum
calcium and phosphate at 1–3 week intervals throughout
the study duration, including at the aforementioned
study visits and additionally at designated safety visits
(visits 4, 7, 9–12). If calcium or phosphate rises above
the upper limit of normal, the test will be repeated in
3 days and subjects will be counseled by our dedicated
study dietician on adherence to a low calcium diet (Diet-
ary Calcium Intake Recommendations Additional file 1).
If calcium or phosphate levels remain elevated, or the
calcium-phosphate product exceeds 50, the dose of study
drug will be reduced by one third. Based on several prior
studies that have employed chronic VDR-agonist therapy
in combination with lowered dietary calcium intake, our
dosing and study duration are unlikely to invoke hyper-
calcemia or hyperphosphatemia [27-29].Blood pressure
During PAH and angiotensin II infusion, blood pressure
(BP) will be monitored every 2 minutes using an auto-
mated sphyngomanometer. An increase in BP is an
expected effect of angiotensin II infusion, and the follow-
ing protocol has been used safely in over 1500 subjects
[5]. The 0.3 ng/kg/min dose was selected because it does
not induce a pressor effect but still influences renal-
vascular hemodynamics [30], and the 1 ng/kg/min dose
was selected because it has previously been shown to in-
duce minimal BP elevations well within a safety range
[5,30]. A study physician will supervise all angiotensin II
infusions as previously described [5].
All subjects will monitor their BP daily with a home
sphygmomanometer while on the washout phase (when
applicable) and while on lisinopril and will communicate
their readings to study staff twice weekly. Study staff will
monitor for unsafe high BP during the washout period
(>159/99 mmHg) or unsafe hypotension during lisinopril
treatment (<90/50 mmHg). Subjects who develop high
BPs during the washout period may be treated with
amlodipine which has a neutral effect on RAS compo-
nents. Subjects who develop low BPs on lisinopril may
have their dose reduced 50%, however, if a 2.5 mg daily
dose is not tolerated, subjects will be removed from the
study.Blood glucose
Subjects will be asked to check their home blood glucose
daily, and study staff will monitor their glycemic control
throughout the study. If fasting morning blood glucose is
consistently >150 mg/dL, medications will be adjusted by
a study physician. Such adjustments include increasingthe dose of a home medication or adding a second oral
hypoglycemic agent.Lipids
Any subject who has a screening LDL cholesterol greater
than 100 mg/dL, will either be prescribed simvastatin
20-40 mg daily, or if already taking a statin medication,
have their pre-existing statin dose increased, to remain
consistent with clinical standards of care for diabetes.Laboratory measurements
25(OH)D (Diasorin, Inc., Stillwater, MN), 1,25(OH)2D
(Diasorin), parathyroid hormone (Beckman Coulter,
Fullerton, CA), and serum and urine electrolytes (including
calcium and phosphate) will be measured at baseline at all
visits. Components of the circulating RAS, including plasma
renin activity (Diasorin) and aldosterone (Siemens, Los
Angeles, CA), will be measured from samples drawn in
upright and supine posture (Visits 2, 5, 13) and before
and during angiotensin II infusion (Visits 3, 6, 8) [5].
For assessment of RPF, para-aminohippurate will be mea-
sured in triplicate at steady-state and during angiotensin
II infusion and will then be adjusted by body surface area
in all RPF calculations (Visits 3, 6, 8).Statistical analyses
Sample size calculations
Sample size calculations were made using our prior data
evaluating the impact of vitamin D on the systemic [23]
and renal-vascular tissue-RAS [5] by paired analyses
with an alpha-error of 0.05. For Aim 1, prior data sug-
gest that therapy with a VDR agonist could reduce
plasma renin activity, a measure of the circulating RAS,
by 1 ng/mL/hr (SD = 0.54). A minimum of 5 subjects
would be required in each study arm for a paired com-
parison to detect this difference with a power of 0.9. In
our pilot intervention study, we demonstrated an effect
of vitamin D therapy on the renal-vascular tissue-RAS
(Aims 2 & 3) in a sample of 14 subjects. To account for
underestimation of sample-size, variability in measure-
ments, and to permit non-paired comparisons, we in-
tend to study 20 subjects in each intervention group.Outcomes
Paired and repeated measures analyses will be used to
evaluate intra-individual changes in the circulating RAS,
RPF responses to angiotensin II infusion (i.e. renal-
vascular tissue-RAS), and urine protein levels. Non-
paired comparisons will be used to evaluate changes in
these parameters between the calcitriol and placebo
groups. A two-tailed P-value < 0.05 will be considered
statistically significant.
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The VALIDATE-D study is a unique randomized and
double-blinded human intervention study that is designed
to elucidate the mechanism by which vitamin D therapy
may impart renoprotective benefits in diabetes. Vitamin D
metabolism and regulation of the RAS are complex pro-
cesses that involve multiple genes, gene-products, and
environmental inputs (Figure 1); the genetic variation,
dietary intake, and other environmental exposures for
each individual have been shown to alter the balance
of each of these hormonal systems [33-35]. In this re-
gard, using supplementation with vitamin D3 in an
intervention study to induce a clinical outcome that is
mediated by the interaction between 1,25(OH)2D and
the VDR (such as RAS inhibition to influence renal-
vascular function) is analogous to administering a pre-
or pro-drug that is dependent on multiple subsequent
enzymatic steps, each regulated and modified by genet-
ics and environment. The strengths of the VALIDATE-
D study are that it focuses on overcoming this individ-
ual variability by investigating the influence of direct
VDR-agonist therapy in modulating RAS activity and
renal-vascular function, and employs a meticulous de-
sign to evaluate the underlying mechanism of potential
findings (regulation of RAS activity).
Increasing evidence highlights a relationship between
vitamin D and the RAS, with relevant implications for
renal-vascular and kidney disease [1,36]. Lowering un-
favorable RAS activity has known vascular benefits in
diabetes [37], and the use of RAS inhibitors is common
practice to prevent or delay the progression of diabetic
nephropathy. Animal studies have elegantly shown that
activating the VDR results in lowering of the renal-
vascular tissue-RAS, and that this interaction translates
to reduced kidney injury, particularly in the setting of ani-
mal models of diabetes [19-21]. While human studies often
focus on influencing clinical outcomes by supplementing
with vitamin D3 [5,38], research studies that employ direct
VDR-agonists may be most effective at invoking VDR-
mediated effects such as RAS modulation [2,39]. The
advantage of using direct VDR-agonists in intervention
studies is that they likely maximize any effect mediated by
the VDR, eliminate inter-individual variations in vitamin D
metabolism, and may influence clinical outcomes in a
shorter duration of time than would take with vitamin D3
supplementation. The disadvantage of using VDR-agonists
is that they are not commonly used in individuals without
CKD and therefore direct clinical translation of study find-
ings is limited; however, positive findings would support
any therapy (vitamin D3 or VDR-agonist) that raises 1,25
(OH)2D levels or activates the VDR as an equal surrogate.
The results of the VALIDATE-D study will shed light
on: 1) the mechanism by which VDR activation influ-
ences renal-vascular function in human diabetes (viamodulation of the RAS), and 2) whether VDR activation
modulates renal hemodynamics and proteinuria in hu-
man diabetes. These findings would not only carry major
implications for the recommendation of vitamin D sup-
plementation in the primary prevention of diabetic ne-
phropathy, but they could help interpret the findings of
many other studies that evaluated clinical outcomes of
vitamin D therapy without accounting for the mecha-
nisms involved. In this regard, the VALIDATE-D study
may explain the reasons prior negative studies failed
to see outcomes and why positive studies may have
succeeded.
At least three unique findings will emerge from the
VALIDATE-D study. First, this intervention study will
conclusively evaluate whether vitamin D therapy lowers
the circulating human RAS. By using direct VDR ago-
nists and a meticulous study design to account for con-
founders of the RAS (diet, posture, medications, time of
day), this study will investigate whether calcitriol therapy
lowers the maximally stimulated RAS on a LS diet in
comparison to placebo. Second, this study will evaluate
whether direct VDR activation improves renal-vascular
hemodynamics by increasing renal blood flow and the
renal-vascular sensitivity to angiotensin II; both of these
observations are consistent with reductions in the renal-
vascular tissue-RAS as would be induced by an ACE in-
hibitor. The study design includes a comparison of
renal-vascular hemodynamics (while the circulating RAS
is suppressed on a HS diet) during treatment with
calcitriol vs. placebo, and then again during treatment
with calcitriol + lisinopril vs. placebo + lisinopril (Figure 2).
In this regard, the study design is optimized to decipher
the individual role of VDR activation, and the effect of
combining VDR activation with conventional RAS inhib-
ition, since this combination therapy has been shown to
provide synergistic renoprotection in animal models of
diabetes [19-21]. The assessment of the renal-vascular
tissue-RAS in humans is a unique and defining aspect of
this study protocol. The renal vasculature is specifically
sensitive to the effects of angiotensin II, and the magni-
tude of renal-vascular responses to angiotensin II is in-
versely proportional to the degree of local tissue-RAS
activity [5,11,16]. High endogenous tissue-RAS activity re-
sults in a blunted local sensitivity to the effect of angioten-
sin II, while inhibiting the local renal-vascular tissue-RAS
(for example with an ACE inhibitor) improves the renal-
vascular sensitivity to angiotensin II [30] (Figure 3). There-
fore, our ability to measure renal hemodynamics via
para-aminohippurate clearance permits us to object-
ively ascertain the state of the renal-vascular tissue-
RAS in response to drug intervention (calcitriol, lisinopril,
placebo) and in response to provocation by angiotensin II.
Lowering renal-vascular tissue-RAS activity in pathologic
states such as diabetes and obesity with conventional
Brown et al. BMC Endocrine Disorders 2013, 13:33 Page 8 of 9
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blocker) has shown efficacy for the primary prevention of
diabetic nephropathy [15,40,41]. Thirdly, the impact of
adding chronic VDR-agonist therapy to ACE inhibitor
therapy on proteinuria will be assessed. Since the study
population is strategically selected to have diabetes with-
out CKD, together these study findings will have implica-
tions for recommending vitamin D supplementation to
lower unfavorable RAS activity for the primary prevention
of diabetic nephropathy.
We have previously shown in a pilot study that high-
dose vitamin D3 therapy to markedly raise 1,25(OH)2D
concentrations can lower renal-vascular tissue-RAS ac-
tivity in non-diabetics with normal renal function [5].
Like an ACE inhibitor, this intervention induced a favor-
able state of low tissue-RAS resulting in increased renal-
vascular sensitivity to angiotensin II [5]. The VALIDATE-D
study will extend these findings by employing a double-
blinded randomization, employing direct VDR agonist
therapy, and focusing on patients with diabetes without
CKD. In prior clinical studies of secondary prevention in
diabetes with pre-existing CKD, direct VDR agonists
(calcitriol and paracalcitol) reduced proteinuria [7,42-45];
whether this effect was mediated by the RAS, or could be
extrapolated for the primary prevention of diabetic ne-
phropathy, are questions that the VALIDATE-D study will
clarify.
VALIDATE-D is the first human study to investigate
whether vitamin D therapy to activate the VDR can
lower circulating and renal-vascular tissue-RAS activity
in diabetics without CKD. This study is designed to spe-
cifically focus on whether modulating the RAS repre-
sents a key mechanism by which vitamin D intervention
impacts renal-vascular hemodynamics and kidney function.
In this regard, VALIDATE-D will provide evidence that
may influence clinical recommendations for maintaining
vitamin D status for the primary prevention of diabetic
nephropathy. In addition, VALIDATE-D will examine
whether the action of potent VDR agonist therapy
complements the known beneficial effects of ACE in-
hibition, as has been observed in animal models [19].
If so, the results of VALIDATE-D could influence
pharmacologic practices by favoring vitamin D3 sup-
plementation instead of, or in addition to, ACE inhibi-
tor therapy for patients with diabetes.Additional file
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